**Title: Sensor Estimated Home 6-Minute Walk Distance and Cardiac Effort in Pulmonary Hypertension and Heart Failure**

Daniel Lachant[1], Nishit Agarwal[2], Kyle Norton[1], Deborah Haight[1], Sebastian Alphonse[2], Brett Meyer[2], Kevin Machado Gamboa[2], Paolo Depetrillo[2], Hailey Patterson[3], Becca Slepian[3], Marvin Slepian[3], R James White[1], Melissa Ceruolo[2]

[1]Division of Pulmonary and Critical Care, University of Rochester Medical Center, Rochester, NY, United States

[2]Medidata a Dassault Systèmes Company, New York, NY, United States
[3]Division of Cardiology, University of Arizona, Tucson, AZ, United States

**Institutional Review Board Approval**: University of Rochester Study 00007451

**Conflict of interest**: Medidata employees helped with data analysis and were funders of the study.

**Funding**: Medidata funded the study and NHLBI 1K23HL171867-01 (to D.L.)

**Abstract:**

**Background**

Sensor-based estimation of six-minute walk distance and Cardiac Effort, number of heartbeats during the walk divided by distance walked, can be measured in the home. This study aimed to evaluate 1) the impact of walking course length on walk distance and Cardiac Effort, and 2) assess changes over time in a cohort of pulmonary hypertension and heart failure participants.

**Methods**

This was a prospective observational study conducted at two sites. Participants included pulmonary hypertension, heart failure, and healthy controls. All participants wore chest-based sensors capable of recording accelerometry and electrocardiographic data. At baseline visit, participants performed a six-minute walk test on both a 90-ft and a 30-ft course, separated by 30-minutes rest. Unsupervised home walk tests were performed on the following two days. All assessments were repeated eight weeks later. Walk distance and Cardiac Effort were

measured using three methods: direct observation, lap count estimation, and a signal-derived method based on mean amplitude deviation. Comparisons between clinic and home-based measurements were made using paired t-tests, correlation analysis, and Bland-Altman testing.

**Results**

Sixty-six participants were enrolled, including 42 with pulmonary hypertension or heart failure and 24 controls. Walk distance on the 90-foot course was 10.7 percent longer than on the 30-ft course. Home-based walk distance was similar to the 30-ft course but lower than the 90-ft course. Home Cardiac Effort was similar to in-clinic values and tracked with changes over time.

**Conclusion**

Home-based functional testing incorporating Cardiac Effort may offer a simple and effective remote metric to improve management of patients with heart failure.

## Introduction

The 6-minute walk test (6MWT), performed according to American Thoracic Society guidelines, is a simple assessment of functional capacity in a supervised clinical setting(1). It requires minimal equipment, a 30 m unobstructed hallway and a healthcare personnel to count laps to calculate a 6-minute walk distance (6MWD). In pulmonary arterial hypertension (PAH), 6MWD provides insight into disease status and treatment response(2). Unfortunately, current 6MWT is limited on how frequent it can be performed. Cardiac Effort (CE)(3-6), the number of heart beats during the 6MWT divided by 6MWD, was developed to provide deeper insight into the physiologic effort required to achieve a certain 6MWD. It helps differentiate whether changes in 6MWD are due to variations in effort or underlying changes in physiology. CE has been incorporated as an exploratory end point in a PAH clinical trial(7), in pulmonary hypertension with

interstitial lung disease (NCT06129240), and in a pulmonary embolism(8) and PAH rehabilitation study (NCT06477640).

The COVID-19 pandemic disrupted routine care in PAH. Interpreting changes in 6MWD became more difficult with masking(9). This led to home 6MWT being performed in pulmonary hypertension (6, 10, 11). All three studies found it was safe to perform 6MWT in the home setting. The first report in PAH found 6MWD at home and in the clinic were similar when performed on 90ft walking space and supervised (10). The second report in PAH showed unsupervised 6MWT performed on a modified walking space (~40ft) using sensor estimated 6MWD was lower than clinic 6MWD, but CE provided a similar measurement (10).The third study in a mix pulmonary hypertension cohort used an app to perform tele-6MWT in a mix group of pulmonary hypertension patients and found tele-6MWT had a bias of 25 m over directly observed 6MWT (11). They did not report how the app performed on directly observed 6MWT.

In this study, we performed in clinic and home 6MWT and CE in a mix pulmonary hypertension and heart failure cohort and evaluated changes overtime. We hypothesized that CE would have less variability when comparing in clinic to home measurements by accounting for changes in heart rate. We did the following, 1) Compared 6MWD and CE on 90-ft and 30-ft walking spaces in the clinic to evaluate the impact of walking space length and the frequency of turns on test results. 2) Compared directly observed, lap-estimated, and mean amplitude deviation (MAD)-estimated 6MWD and CE values obtained in the clinic to those obtained during home monitoring at each time point. 3) Compared changes in 6MWD and CE from baseline to Week-8 during home monitoring to corresponding changes observed in the clinic.

**Methods:**

This was a prospective observational study conducted at the University of Rochester Medical Center and the University of Arizona. Institutional Review Board approval was obtained. The study development and analysis were performed collaboratively by the authors, with Metadata sponsoring the study. We selected a chest-based form factor for the wearable sensor to ensure the highest data quality, as this placement facilitates superior cardiac data collection via ECG during ambulation compared to wrist-based photoplethysmography (PPG) sensors, which is crucial for accurately computing the Cardiac Effort metric from both heart rate and acceleration data. All participants provided informed consent before any study activities were performed. Participants with treated pulmonary hypertension or heart failure were eligible to participate. We included a small cohort of Heart Failure (HF) patients alongside the Primary Pulmonary Hypertension (PH) cohort to explore the utility of the Cardiac Effort metric in a heterogeneous group of cardiopulmonary-limited patients. There was also a control cohort that was not age sex matched to see the impact of longer walkers. Recruitment occurred between September 2022- February 2024 as they were seen during routine clinic visits. Participants needed to be functional class I-III, ambulatory, and have an unobstructed walking space of at least 30ft at home. Participants did not wear a mask during the in-clinic or at-home study procedures. Safety measures for the at-home walks included requiring a caregiver to be present, with no adverse events reported.

Baseline testing included demographics, clinical characteristics, quality of life questionnaire (emPHasis-10(12) or Minnesota Living with Heart Failure questionnaire(13)), NT-pro BNP, and Reveal lite 2 score(14) in pulmonary hypertension only. The BioStamp nPoint® (Medidata), a medical-grade wearable patch has been previously validated to measure accelerometry and electrocardiography(15) and used in this pilot study(6), was placed on the left upper chest and thigh with disposable adhesive prior to the 6MWT [Figure 1]. Accelerometry and electrocardiography data was recorded at 31.25 Hz and 250 Hz, respectfully. Concurrently we

utilized the VitalPatch® (VitalConnect), a disposable wearable patch also measuring accelerometry (50 Hz) and electrocardiography (125 Hz), validated for remote vitals data collection(16, 17). Both devices are FDA cleared for medical use. Participants rested for 3 minutes before the first 6MWT. At each visit participants completed two 6MWT, 90ft walking space (1) and a second on a 30ft walking space, with a 30 minute rest between 6MWT. After the second 6MWT, participants went home wearing one of the devices. Due to supply chain issues, 26 subjects wore BioStamp nPoint only for the two visits, 24 wore both BioStamp nPoint for two visits and VitalPatch for the second visit only, and 16 wore BioStamp nPoint and VitalPatch during both visits. Data from both devices was collected and transmitted to a secure cloud for analysis. The goal was not to compare sensors. On day 1 and 2, a home 6MWT on a modified walking space was performed. The course length was recorded by the participant using a 100 ft tape measure. Safety assessment was performed to evaluate for syncope, falls, or other safety concerns related to home 6MWT or devices. Eight weeks (+/- 7 days) later participants would complete the same evaluation as baseline, only this time the order of 6MWT on the 90ft and 30ft were switched.

6MWD in clinic was calculated three different ways on the 90 and 30 ft walking spaces: 1) directly observed distance ($6MWD_D$), 2) estimating distance based on lap counting with accelerometry ($6MWD_L$, as previously described)(6), and 3) estimating distance based on changes in mean amplitude deviation (MAD) ($6MWD_M$, as previously described, distance estimated by changes in acceleration units)(6). These were the same methods used in this prior report(6). In the home setting, 6MWD was estimated using 1) lap counting and 2) changes in MAD. Cardiac Effort (CE) was calculated as previously described(4, 6) using all three 6MWD methods ($CE_D$, $CE_L$, $CE_M$). The electrocardiography heart rate data was analyzed using LabChart 8 (AdInstruments).

Categorical variables were reported as counts and percent. Continuous variables were reported as median with interquartile range. Correlations were performed with Pearson or Spearman depending on the distribution of the data. Bland-Altman was used to compare measurements. We compared directly observed 6MWD and Cardiac Effort to estimated methods. The 90ft measurements were compared to 30ft measurements. The in-clinic measurements were compared to home measurements and repeat in clinic and home measurements were compared for reproducibility. Parametric and non-parametric t testing were performed depending on the distribution of the data.

**Results:**

**Baseline demographics**

Sixty-six participants were enrolled, 31 with pulmonary hypertension, 11 heart failure, and 24 controls [Table 1]. Th majority of pulmonary hypertension participants were middle aged, the heart failure participants were older, and the healthy controls were younger. There were 10 participants with functional class III symptoms. The baseline $6MWD_D$ and $CE_D$ for all participants were 434 m and 1.47 beats/m [Table 1]. The average home walking space was 37ft. Out of 459 walks, 26 electrocardiography tracings were not usable because of artifacts (Supplement Table 1]). All 66 participants completed baseline testing. However, the longitudinal analysis comparing baseline clinic data against the eight-week home follow-up data was limited to 55 participants. The remaining 11 participants (5 healthy controls, 4 PAH, and 2 heart failure patients) were excluded from the longitudinal cohort as they only had data available from the baseline visit. Clinical worsening contributed to non-control participants missing the week-8 visit. For controls, relocating and COVID infections limited week-8 follow up. There was near 100% compliance with walks at home with only two home walks not being performed.

**Safety**

Importantly, with 10 functional class III and 5 participants on supplemental oxygen, there were no issues related to the devices, falls, tripping on oxygen tubing, syncope, or unexpxected emergency room visits related to the home 6MWT.

**6MWD and Cardiac Effort 90 and 30 ft In Clinic**

$6MWD_D$ and $CE_D$ on 90 and 30 ft for all participants are listed in [Table 2]. The $6MWD_D$ and $CE_D$ were both better on the 90ft walking space; even when 30ft walking course was performed first. Positive correlations were observed between measurements obtained on 90ft and 30ft walking spaces for both $6MWD_D$ ($r=0.966$, $p<0.005$) and $CE_D$ ($r=0.941$, $p<0.005$), respectively. In Figure 2, Bland-Altman analysis revealed mean differences of 10.73% for $6MWD_D$ and -9.91% for $CE_D$ between measurements obtained on 90ft and 30ft walking spaces.

**6MWD and Cardiac Effort Estimate In Clinic**

There were no differences between $6MWD_D$ on 90ft walking space or 30ft walking space with $6WMD_L$ (n=118), (447 m (366, 515) vs 429m (356, 506) p=0.22) and (401 m (313, 454) vs 399 m (321, 461) p=0.96). In Figure 3-4, Bland Altman analysis shows that $6WMD_L$ was 3.79% different from $6WMD_D$ on the 90ft walking space and 1.40% on 30 ft walking space. Five walks could not have a distance estimated because turns could not be identified. Correlation analysis shows $6WMD_L$ is positively correlated to $6WMD_D$ on the 90ft walking space ($r=0.97$, $p<0.005$) and on the 30 ft walking space ($r=0.99$, $p<0.005$).

There was no difference between $6MWD_D$ on 90ft walking space and $6WMD_M$ (n=117) (445 m (366, 515) vs 441 m (380, 514) p=0.21). The $6MWD_D$ on the 30 ft walking space was shorter than the $6MWD_M$ (401 m (313, 454) vs 412 m (338, 481), p=0.03). This could be from movement during extra turns that MAD captures. In Figure 3-4, Bland Altman analysis shows that $6MWD_M$ was 0.76% different from $6MWD_D$ on the 90ft walking space and -2.91% on 30 ft walking

space. Correlation analysis shows $6WMD_M$ is positively correlated to $6WMD_D$ on the 90ft walking space (r=0.93, p<0.005) and on the 30 ft walking space (r=0.93, p<0.005).

There was no difference between $CE_D$ on 90ft walking space or 30ft walking space with $CE_L$ (n=113), (1.47 beats/m (1.20, 1.81) vs 1.51 beats/m (1.27, 1.81), p=0.36) and (1.62 beats/m (1.35, 1.99) vs 1.60 (1.36, 1.94) p=0.47). In Figure 3-4, Bland Altman analysis shows that $CE_L$ was -2.3% different from $CE_D$ on the 90ft walking space and 0.28% on 30ft walking space. Correlation analysis shows $CE_L$ is highly correlated to $CE_D$ on the 90ft walking space (r=0.97, p<0.005) and on the 30 ft walking space (r=0.99, p<0.005).

There was no significant difference between $CE_D$ on 90ft walking space and $CE_M$ (n=112) (1.47 beats/m (1.20, 1.81) vs 1.49 beats/m (1.24, 1.76) p=0.56). The $CE_D$ on the 30 ft walking space was higher than the $CE_M$ (1.62 beats/m (1.35, 1.99) vs 1.58 (1.33, 1.88), p=0.02). This could be from acceleration changes related to the extra turns that mean amplitude captures. In Figure 3-4, Bland Altman analysis shows that $CE_M$ was -0.21% different from directly observed Cardiac Effort on the 90ft walking space and 3.59% on 30 ft walking space. Correlation analysis shows $CE_M$ is highly correlated to $CE_D$ on the 90ft walking space (r=0.87, p<0.005) and on the 30 ft walking space (r=0.85, p<0.005).

**In clinic vs at home Lap Estimated 6MWD and Cardiac Effort**

Using $6MWD_L$, the 90ft clinic $6MWD_L$ was further than the home $6MWD_L$ (baseline, 434 m (367, 502) vs 400 m (323, 507), p=0.0025) and (week 8, 464 m (368, 566) vs 390 m (329, 508), p<0.0001). There was no difference between $6MWD_L$ on the 30ft walking space with the home $6MWD_L$ (baseline, 400 m (334, 466) vs 400 m (323, 507), p=0.75) and (week 8, 412 m (344, 490) vs 390 m (329, 508), p=0.12). In Figure 5-6, Bland-Altman analysis revealed $6MWD_L$ at home was 8.21% different from $6MWD_L$ in clinic on the 90ft walking space and -0.36% different from $6MWD_L$ in clinic on the 30ft walking space. Correlation analysis revealed $6MWD_L$ at home is

correlated to $6MWD_L$ in clinic both on the 90ft (r=0.89, p<0.005) and 30ft (r=0.9, p<0.005) walking spaces.

Using $CE_L$, home $CE_L$ was higher than 90ft $CE_L$ in clinic at baseline, (1.53 beats/m (1.27, 1.91) vs 1.63 beats/m (1.38, 1.99), p=0.01) and week 8 (1.51 beats/m (1.22, 1.79) vs 1.58 beats/m (1.36, 2.01), p=0.008). There was no difference at baseline or week 8 between $CE_L$ on the 30ft walking space with the home $CE_L$ (1.58 beats/m (1.36, 2.22) vs 1.63 beats/m (1.39, 1.99), p=0.62) and (1.62 beats/m (1.38, 1.94) vs 1.57 beats/m (1.41, 2), p=0.89). In Figure 5-6, Bland-Altman analysis revealed $CE_L$ at home was -6.9% different from $CE_L$ in clinic on the 90ft walking space and -0.11% different from $CE_L$ in clinic on the 30ft walking space. Correlation analysis revealed $CE_L$ at home is correlated to $CE_L$ in clinic both on the 90ft (r=0.7, p<0.005) and 30ft (r=0.77, p<0.005) walking spaces.

Using pooled $CE_L$ (to account for the different order of in clinic tests completed) at baseline and week 8 from pulmonary hypertension and heart failure participants only, we observed that $CE_L$ at home was higher than $CE_L$ in clinic for the 90ft walking space in clinic (1.70 beats/m (1.48, 2.24) vs 1.82 beats/m (1.58, 2.26), p=0.03), while 30ft walking space in clinic was similar to at home (1.84 beats/m (1.60, 2.36) vs 1.82 beats/m (1.58, 2.26), p=0.80). Using pooled $6MWD_L$ from pulmonary hypertension and heart failure participants only, we observed $6MWD_L$ in clinic for the 90 ft walking was further than home $6MWD_L$ (415 m (284, 474) vs 365 m (304, 417), p = 0.0003), while there was no difference with 30ft walking space in clinic versus at home (378 m (271, 429) vs 365 m (304 ,417), p = 0.65).

**In clinic vs at home Mean Amplitude Deviation 6MWD and Cardiac Effort**

Using $6MWD_M$, there was a similar finding of the 90ft $6MWD_M$ being further than the home $6MWD_M$ (baseline, 438 m (381, 514) vs 411 m (315, 490), p<0.0001) and week 8, 449 m (361,

542) vs 390 m (304, 462), p<0.0001). There was no difference at baseline between $6MWD_M$ on the 30ft walking space with the home $6MWD_M$ (419 m (346, 472) vs 411 m (315, 490), p=0.09). However, during week 8 visit we observed a significant difference (415 m (332, 504) vs 392 m (310, 485), p=0.0007). In Figure 5-6, Bland-Altman analysis revealed $6MWD_M$ at home was 12.1% different from $6MWD_M$ in clinic on the 90ft walking space and 5.27% different from $6MWD_M$ in clinic on the 30ft walking space. Correlation analysis revealed $6MWD_M$ at home is correlated to $6MWD_M$ in clinic both on the 90ft (r=0.9, p<0.005) and 30ft (r=0.91, p<0.005) walking spaces.

Using $CE_M$, the 90ft $CE_M$ was different than what was obtained at home (baseline, 1.51 beats/m (1.35, 1.80) vs 1.67 beats/m (1.40, 2.02), p=0.0001) and week 8, 1.55 beats/m (1.32, 1.85) vs 1.70 beats/m (1.48, 2.0), p=<0.0001). There was no difference at baseline or week 8 between 30 ft $CE_M$ with the home $CE_M$ (1.57 beats/m (1.39, 1.97) vs 1.67 beats/m (1.40, 2.02), p=0.25) and (1.62 beats/m (1.33, 1.94) vs 1.67 beats/m (1.45, 2.0), p=0.36). In Figure 5-6, Bland-Altman analysis revealed $CE_M$ at home was -7.93% different from $CE_M$ in clinic on the 90ft walking space and -2.20% different from mean amplitude estimated Cardiac Effort in clinic on the 30ft walking space. Correlation analysis revealed $CE_M$ at home is correlated to $CE_M$ in clinic both on the 90ft (r=0.85, p<0.005) and 30ft (r=0.85, p<0.005) walking spaces.

Pooled $CE_M$ in clinic on 90 ft walking space was different from home $CE_M$ (1.69 beats/m (1.51, 2.00) vs 1.84 beats/m (1.65, 2.15), p<0.0001), while there was no difference with 30 ft $CE_M$ and home $CE_M$ (1.81 beats/m (1.57, 2.13) vs 1.84 beats/m (1.65, 2.15) p=0.60). Pooled $6MWD_M$ in clinic on 90 ft walking space was different from home $6MWD_M$ (413 m (320, 484) vs 348 m ( 275, 429), p < 0.0001) and 30ft walking space (371 m (295, 446) vs 348 m( 275, 429), p = 0.01).

**Changes in clinic vs at home**

In pulmonary hypertension and heart failure participants only, we found changes in $6MWD_M$ at home correlated with changes with both $6MWD_D$ (r=0.33, p=0.02) and $6MWD_M$ (r=0.31, p=0.04) on 30ft walking space. Changes in $CE_L$ on 90ft and 30ft correlated with changes in $CE_L$ at home (r=0.73, p<0.0001 and r=0.61, p=0.0001). Changes in $CE_D$ on 90ft and 30ft correlated with changes in $CE_M$ at home, (r=0.47, p=0.002 and r=0.62, p=0.00002). There was similar finding with changes in $CE_M$ on 90ft and 30ft changes with $CE_M$ at home (r=0.50, p=0.001 and r=0.62, p<0.00001).

**Discussion**

This two-center study demonstrates that unsupervised home 6MWT, when combined with heart rate monitoring and conducted on a modified walking course, is safe, feasible, and associated with high participant compliance across a broad range of individuals with pulmonary hypertension and heart failure. A cohort of non-cardiopulmonary limited controls was included to explore and establish a benchmark for highly functional data in the home 6-minute walk setting, allowing us to better understand the performance characteristics of the metric in a less-impaired population. We found that sensor-derived CE and 6MWD estimates, using two distinct methods, closely matched directly observed values collected in the clinic, supporting their validity for remote monitoring. As expected, all three measurement methods (direct observation, lap estimation, MAD) showed that 6MWD was greater (~11%) on a 90-ft walking course compared to a 30-ft course or the unsupervised home setting. This difference is likely due to the reduced number of turns required on the longer course. Incorporating heart rate monitoring during the 6MWT and calculating CE helped account for variable effort in the home, providing measurements similar to those observed in the clinic. Changes in CE measured at home were strongly associated with changes observed in the clinic, highlighting the utility of this monitoring approach for tracking changes in physiologic or functional status remotely. This novel method offers broad applicability, particularly in rural, urban, or lower socioeconomic settings where clinic access may be limited,

as well as in specialized care centers where patients frequently travel long distances for routine follow-up or assess for treatment response.

There is interest with incorporating passive monitoring using wearable devices in pulmonary hypertension and heart failure. Actigraphy has been included as endpoints in randomized controlled PAH (18, 19), interstitial lung disease (20-22), and heart failure (23) clinical trials. A common finding to all studies has been low activity time; likely from behavioral changes, deconditioning, and underlying cardiopulmonary disease. This makes assessing for therapeutic changes difficult. In PAH, top bursts of activity, peak 5-minute steps, has been shown to increase after adding therapy in two uncontrolled studies(24, 25). More recently, heart rate has been incorporated into the analysis of daily steps to provide more granular insights into the physiologic changes involved in achieving steps (26). Peak steps 5-minute steps and Daily Heart Rate per Step are passive measurements of unstructured home 6MWT and CE. Instead of relying on wrist-based step classification algorithms, that have biases, and error in heart rate measurement with photoplethysmography(3, 4, 6), a structured home 6MWT with a chest-based sensor seems easier to perform, analyze, and trend over time.

There are multiple ways to estimate 6MWD at home including wearables(6, 27), smartphones (28, 29), or global position satellite(30). The type of method can influence the results depending on where it is performed. When using a smartphone app to estimate 6MWD in pulmonary hypertension(31), there was an average difference (standard deviation) of 15 m (76) from the same walk when comparing app estimated 6MWD to directly observed 6MWD. In contrast, when 6MWT was completed outside, presumably with less turns, and compared to directly observed 6MWD indoors, there was an average difference of 2 m (47). These differences highlight the impact the type of monitoring can have when estimating 6MWD and where they can best be implemented. We showed two easy methods for estimating 6MWD based on changes in accelerometry (mean amplitude deviation) and counting laps as long as the course distance is

known(6). Measuring truncal movement through a chest-based sensor decreases artifact and allows for estimates to be made in an indoor setting. There was high correlation with directly observed 6MWD and lap estimated 6MWD on 30 ft and 90 ft walking courses. We did find this approach had more error in lower 6MWD when a participant may stop and rest. This can interfere with detecting turns. In this instance, changes in MAD could help correct or verify walk distance. The added benefit of $6MWD_M$ is course distance is not needed for estimation. As long as a walking gait is unchanged during monitoring, this value could be easily trended over time. Not only can $6MWD_M$ be performed at home, it could also serve in real time to verify 6MWD in a clinical trial to make sure there are no large walk discrepancies due to counting errors. In this present study, we found one error in data entry after identifying a discrepancy between directly observed 6MWD with sensor estimated 6MWD. The source document was reviewed and the reported 6MWD matched with the sensor estimated 6MWD.

By incorporating continuous heart rate monitoring during the 6MWT and calculating CE, we can gain insight into the physiologic stress needed to achieve a certain 6MWD. CE has been shown previously to have less variability than 6MWD, correlates strongly with stroke volume, and tracks with clinical improvement (as cardiac output improves the number of heart beats used during 6MWD decreases)(3-6). Especially in an unsupervised home setting, CE helps provide context for a given estimated 6MWD, specifically whether changes were due to worsening physiology or effort. In this report, we found the greatest value of CE was the changes observed in clinic correlated very strongly with changes at home. This provides an opportunity to monitor therapeutic titration or higher risk patients more closely with sensors.

In the initial reporting of a home 6MWT in PAH (10), participants completed in-clinic and home 6MWT on 90ft walking space with a study team member supervising the walks and found similar 6MWD. Having access to a 90ft walking space year-round with supervision by a healthcare team member at home is not a realistic way to complete testing. In our initial report

(6) we found unsupervised estimated 6MWD at home on a modified walking space was lower than directly supervised 6MWD on a 90 ft walking space. At the time, we were unsure if this was due to effort or extra turns. By comparing 90 ft to 30 ft 6MWD in clinic on the same day, we showed the course length (and resulting turns) will influence home 6MWD independent of effort when not supervised, and highlights the value of CE. A follow up study used an app to perform tele-6MWT in a mix group of pulmonary hypertension patients and found tele-6MWT had a bias of 25 m over directly observed 6MWT (11). Unless it is related to learning the test, it is hard to image how someone would walk further when unsupervised at home compared to directly supervised 6MWT. Future studies are needed to compare the best mode of estimating 6MWD.

Unsupervised home 6MWT is safe. Including this study, there have now been five reports showing unsupervised home 6MWT can be completed without tripping on oxygen tubing, syncope, or emergency room visits (6, 10, 11, 31). Feedback from participants during this study included a discomfort of doing the 6MWT outside, a similar finding that has been shown previously(11, 30). The indoor test provides comfort about being able to stop and rest if needed, not having to worry about bringing oxygen outside, weather, or walking back once completed. Participants also reported that they liked doing the test in their home as compared to the clinic and got them moving more at home. Therefore, having a home indoor option is extremely valuable for acceptance.

There are limitations to our study. Participants were enrolled as they were seen in the clinic and therefore clinical status could change as there was no screening period for stability. The study was completed during the COVID-19 pandemic and infections impacted follow up. Because of COVID related restrictions with scheduling, there was no room to schedule follow up outside of the week 8 window. We did not design this study to assess therapeutic response. There was electrocardiography data loss when using the manufacturer recommended body location on some patients. A dry electrode chest strap can be an alternative to patch sensors for

Cardiac Effort. A potential limitation is the learning effect associated with the unsupervised nature of the at-home version of the test.

In conclusion, in this two-center study we confirm the previous finding that wearable devices with electrocardiography and accelerometry provide a way for 6MWT and CE to be performed safely in the home setting in pulmonary hypertension and heart failure. The measurements track in the same direction as clinic assessments overtime. More frequent assessments between visits could allow for changes in physiology to be identified sooner. Home 6MWT and CE could be performed in all settings (rural or urban) at a fraction of the cost of other tests. Importantly, there was high patient acceptance and compliance with testing. Future studies can compare the effectiveness of using home 6MWT and CE to help with risk assessment or therapeutic response.

## References


1. ATS statement: guidelines for the six-minute walk test. American journal of respiratory and critical care medicine. 2002;166(1):111-7.
2. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). European Heart Journal. 2022;43(38):3618-731.
3. Lachant DJ, Light AN, Mackin ML, Schwartz RG, White RJ. Heart Rate Expenditure Correlates with Right Ventricular Function. Ann Am Thorac Soc. 2019.
4. Lachant DJ, Light A, Offen M, Adams J, White RJ. Heart rate monitoring improves clinical assessment during 6-min walk. Pulmonary Circulation. 2020;10(4):2045894020972572.
5. Lachant DJ, Lachant MD, Haight D, White RJ. Cardiac effort and 6-min walk distance correlate with stroke volume measured by cardiac magnetic resonance imaging. Pulm Circ. 2024;14(2):e12355.
6. Lachant D, Kennedy E, Derenze B, Light A, Lachant M, White RJ. Cardiac Effort to Compare Clinic and Remote 6-Minute Walk Testing in PAH. Chest. 2022.
7. Frantz RP, Benza RL, Channick RN, Chin K, Howard LS, McLaughlin VV, et al. TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulmonary Circulation. 2021;11(4):20458940211057071.
8. Lachant D, Haight D, Roto D, Williams A, Norton K, White RJ. Electronically delivered rehabilitation after acute pulmonary embolism is safe and improves quality of life. Eur Respir J. 2024.
9. Wissmüller M, Wartner V, Hohmann C, Adler J, Kramer T, Hellmich M, et al. Impact of face masks on the 6-minute walk distance in pulmonary hypertension patients during the COVID-19 pandemic: a prospective, randomised cross-over study. European Respiratory Journal. 2023;62(4):2201454.
10. LaPatra T, Baird GL, Goodman R, Pinder D, Gaffney M, Klinger JR, et al. Remote 6-Minute-Walk Testing in Patients with Pulmonary Hypertension: A Pilot Study. American journal of respiratory and critical care medicine. 2022;205(7):851-4.
11. Stubbs H, Lua S, Ingram J, Jani BD, Brewis M, Church C, et al. Remote exercise testing in pulmonary hypertension (PHRET). Pulm Circ. 2023;13(4):e12325.
12. Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014;43(4):1106-13.
13. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992;124(4):1017-25.
14. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest. 2021;159(1):337-46.
15. Sen-Gupta E, Wright DE, Caccese JW, Wright Jr JA, Jortberg E, Bhatkar V, et al. A Pivotal Study to Validate the Performance of a Novel Wearable Sensor and System for Biometric Monitoring in Clinical and Remote Environments. Digital Biomarkers. 2019;3(1):1-13.
16. Selvaraj N, Nallathambi G, Moghadam R, Aga A, editors. Fully Disposable Wireless Patch Sensor for Continuous Remote Patient Monitoring. 2018 40th Annual International

Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); 2018 18-21 July 2018.
17. Selvaraj N. Long-term remote monitoring of vital signs using a wireless patch sensor. 2014 IEEE Healthcare Innovation Conference (HIC). 2014:83-6.
18. Howard LS, Rosenkranz S, Frantz RP, Hemnes AR, Pfister T, Hsu Schmitz SF, et al. Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE). Chest. 2022.
19. Kawut SM, Feng R, Ellenberg SS, Zamanian R, Bull T, Chakinala M, et al. Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial. American journal of respiratory and critical care medicine. 2024.
20. Nathan SD, Rajicic N, Dudenhofer R, Hussain R, Argula R, Bandyopadhyay D, et al. Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Am Thorac Soc. 2024.
21. Nathan SD, Flaherty KR, Glassberg MK, Raghu G, Swigris J, Alvarez R, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis. Chest. 2020;158(2):637-45.
22. King CS, Flaherty KR, Glassberg MK, Lancaster L, Raghu G, Swigris JJ, et al. A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. Annals of the American Thoracic Society. 2021;19(4):594-602.
23. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2015;373(24):2314-24.
24. Lachant D, Gagermeier J, Seaman S, Wang A, Broderick M, James White R. Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil. JHLT Open.
25. Lachant D, Light A, Lachant M, Annis J, Hemnes A, Brittain E, et al. Peak steps: Capacity for activity improves after adding approved therapy in pulmonary arterial hypertension. Pulmonary Circulation. 2023;13(3):e12285.
26. Chen Z, Wang CT, Hu CJ, Ward K, Kho A, Webster G. Daily Heart Rate per Step: A Wearables Metric Associated With Cardiovascular Disease in a Cross-Sectional Study of the All of Us Research Program. Journal of the American Heart Association. 2025;14(9):e036801.
27. Schulte J, Duc NA, Hoang DB, Elliott D, McKinley S, Nanda P, editors. A remote sensor-based 6-minute functional walking ability test. SENSORS, 2012 IEEE; 2012 28-31 Oct. 2012.
28. Ata R, Gandhi N, Rasmussen H, El-Gabalawy O, Gutierrez S, Ahmad A, et al. Clinical validation of smartphone-based activity tracking in peripheral artery disease patients. npj Digital Medicine. 2018;1(1).
29. Mak J, Rens N, Savage D, Nielsen-Bowles H, Triggs D, Talgo J, et al. Reliability and repeatability of a smartphone-based 6-min walk test as a patient-centred outcome measure. European Heart Journal - Digital Health. 2021;2(1):77-87.
30. Wevers LEG, Kwakkel G, Van De Port IGL. Is outdoor use of the six-minute walk test with a global positioning system in stroke patients' own neighbourhoods reproducible and valid? Journal of rehabilitation medicine. 2011;43(11):1027-31.
31. Salvi D, Poffley E, Tarassenko L, Orchard E. App-Based Versus Standard Six-Minute Walk Test in Pulmonary Hypertension: Mixed Methods Study. JMIR Mhealth Uhealth. 2021;9(6):e22748.

Table 1 Baseline Demographics

| | PAH/CTEPH (n = 31) | Heart Failure (n = 11) | Control (n = 24) |
|---|---|---|---|
| **Age, median (IQR), years** | 57 (44, 68) | 73 (65, 76) | 27 (24, 62) |
| **Sex, female, No. (%)** | 23 (74) | 6 (55) | 8 (33) |
| **Body Mass Index, median (IQR), kg/m2** | 32 (27, 41) | 26 (23, 37) | 26 (24, 28) |
| **Height, median (IQR), cm** | 163 (160, 173) | 172 (164, 178) | 175 (165, 179) |
| **Weight, median (IQR), kg** | 88 (71, 109) | 74 (69, 101) | 75 (71, 90) |
| **NT-pro BNP, median (IQR), pg/mL** | 181 (83, 368) | 283 (104, 1,418) | — |
| **Functional class (I/II/III), No. (%)** | 0/ 25(81)/ 6(19) | 1(9)/ 6(55)/ 4(36) | — |
| **EmPHasis 10 Questionnaire, median (IQR)** | 26 (20, 37) | — | — |
| **Minnesota Questionnaire, median (IQR)** | —- | 9 (6, 21) | — |
| **Pulmonary Hypertension etiology, No. (%)** | | | |
| **Idiopathic** | 17 (55) | — | — |
| **Connective tissue disease** | 7 (23) | — | — |
| **Heart Failure etiology, No. (%)** | | | |
| **Preserved Ejection Fraction** | — | 6 (55) | — |
| **Reduced Ejection Fraction** | — | 5 (45) | — |
| **Hemoglobin, median (IQR), g/dL** | 14 (13, 15) | 14 (13, 14.5) | — |
| **Baseline 6-Minute Walk Distance (90ft)** | 420 (292, 472) | 358 (338, 491) | 463 (421, 609) |
| **Baseline 6-Minute Walk Distance (30ft)** | 375 (284, 423) | 302 (264, 399) | 441 (401, 553) |
| **Baseline Cardiac Effort (90ft)** | 1.76 (1.5, 2.1) | 1.52 (1.24, 1.8) | 1.24 (1.12, 1.37) |
| **Baseline Cardiac Effort (30ft)** | 1.90 (1.60, 2.3) | 1.71 (1.54, 2.2) | 1.35 (1.21, 1.48) |

Table 2 – 6-Minute Walk Distance and Cardiac Effort at Baseline and Week 8

| | **6-Minute Walk Distance** | | | | | |
|---|---|---|---|---|---|---|
| | **Directly Observed** | | **Lap Estimated** | | **Mean Amplitude Deviation** | |
| | **PH/HF (n = 42)** | **Control (n = 24)** | **PH/HF (n = 42)** | **Control (n = 24)** | **PH/HF (n = 42)** | **Control (n = 24)** |
| **Baseline 6MWD (90ft) – Clinic, (IQR), m** | 416 (317,472) | 463 (421, 609) | 384 (285, 466) | 452 (411, 604) | 404 (315, 483) | 486 (420, 575) |
| **Baseline 6MWD (30ft) – Clinic, (IQR), m** | 373 (284, 416) | 441 (401, 553) | 370 (269, 413) | 430 (388, 550) | 370 (282, 439) | 461 (404, 551) |
| **Baseline Cardiac Effort (90 ft) – Clinic, (IQR), beats/m** | 1.7 (1.5, 2.2) | 1.2 (1.1, 1.4) | 1.7 (1.5, 2.2) | 1.3 (1.1,1.4) | 1.7 (1.5, 2.0) | 1.3 (1.1, 1.4) |
| **Baseline Cardiac Effort (30 ft) – Clinic, (IQR), beats/m** | 1.8 (1.6, 2.4) | 1.4 (1.2, 1.5) | 1.9 (1.6, 2.3) | 1.4 (1.3, 1.5) | 1.8 (1.6, 2.1) | 1.3 (1.2, 1.4) |
| **Baseline 6MWD – Home, (IQR), m** | - | - | 373 (305, 436) | 502 (395, 579) | 375 (287, 449) | 493 (405, 574) |
| **Baseline Cardiac Effort – Home, (IQR), beats/m** | - | - | 1.8 (1.5, 2.2) | 1.4 (1.3, 1.5) | 1.9 (1.6, 2.1) | 1.4 (1.3, 1.5) |
| **Week 8 6MWD (90ft) – Clinic, (IQR), m** | 429 (305, 471) | 529 (463, 615) | 419 (304, 470) | 519 (418, 616) | 434 (336, 482) | 538 (483, 576) |
| **Week 8 6MWD (30ft) – Clinic, (IQR), m** | 380 (283, 419) | 469 (404, 564) | 391 (285, 427) | 467 (398, 563) | 379 (317, 441) | 501 (458, 539) |
| **Week 8 Cardiac Effort (90 ft) – Clinic, (IQR), beats/m** | 1.7 (1.5, 2.1) | 1.1 (1.1, 1.3) | 1.7 (1.4, 2.2) | 1.2 (1.1, 1.4) | 1.6 (1.5, 1.9) | 1.2 (1.1, 1.3) |
| **Week 8 Cardiac Effort (30 ft) – Clinic, (IQR), beats/m** | 1.9 (1.6, 2.3) | 1.4 (1.2, 1.5) | 1.8 (1.6, 2.3) | 1.4 (1.2, 1.5) | 1.7 (1.6, 2.1) | 1.3 (1.1, 1.3) |
| **Week 8 6MWD – Home, (IQR), m** | - | - | 347 (290, 410) | 486 (347, 548) | 348 (266, 412) | 506 (353, 557) |
| **Week 8 Cardiac Effort – Home, (IQR), beats/m** | - | - | 1.8 (1.6, 2.4) | 1.4 (1.2, 1.6) | 1.8 (1.7, 2.2) | 1.3 (1.2, 1.5) |

6-Minute Walk Distance (6MWD), Pulmonary Hypertension (PH), Heart Failure (HF), Median with interquartile ranges.




**Figure 1.** Device placement and study protocol. (Left) Location of BioStamp nPoint and VitalPatch placed concurrently on the chest. (Right) Study protocol: two visits were conducted, each consisting of two 6-minute walk tests (6MWT), one on a 90 ft walking space and the other on a 30 ft walking space. At each visit, participants completed their study protocol and then went home wearing one of the devices.




**Figure 2.** Agreement analysis for 6-minute walk distance (6MWD) and Cardiac Effort (CE) measurements obtained on different walking space lengths. (Left) Bland Altman Plot showing the agreement between 6MWD values obtained on a 90 ft vs 30 ft walking space. (Right) Bland Altman Plot showing the agreement between CE values obtained on a 90 ft vs 30 ft walking space.




**Figure 3.** Agreement between estimated and directly observed walk distances and cardiac efforts on a 90ft walking space. (Top left) Bland-Altman plot of lap-estimated 6MWD vs directly observed 6MWD on a 90ft walking space. (Top right) Bland-Altman plot of lap-estimated Cardiac Effort vs directly observed Cardiac Effort on a 90ft walking space. (Bottom left) Bland-Altman plot of mean amplitude deviation estimated 6MWD vs directly observed 6MWD on a 90ft walking space. (Bottom right) Bland-Altman plot of mean amplitude deviation estimated Cardiac Effort vs directly observed Cardiac Effort on a 90ft walking space




**Figure 4.** Agreement between estimated and directly observed walk distances and cardiac efforts on a 30ft walking space. (Top left) Bland-Altman plot of lap-estimated 6MWD vs directly observed 6MWD on a 30ft walking space. (Top right) Bland-Altman plot of lap-estimated Cardiac Effort vs directly observed Cardiac Effort on a 30ft walking space. (Bottom left Bland-Altman plot of mean amplitude deviation estimated 6MWD vs directly observed 6MWD on a 30ft walking space. (Bottom right) Bland-Altman plot of mean amplitude deviation estimated Cardiac Effort vs directly observed Cardiac Effort on a 30ft walking space.




**Figure 5.** Agreement between in clinic vs at home assessment walk distances and cardiac efforts. (Top left) Bland-Altman plot of lap-estimated 6MWD at home vs lap-estimated 6MWD in clinic on a 90ft walking space. (Top right) Bland-Altman plot of lap-estimated Cardiac Effort at home vs lap-estimated Cardiac Effort in clinic on a 90ft walking space. (Bottom left) Bland-Altman plot of mean amplitude deviation estimated 6MWD at home vs mean amplitude deviation estimated 6MWD in clinic on a 90ft walking space. (Bottom right) Bland-Altman plot of mean amplitude deviation estimated Cardiac Effort at home vs mean amplitude deviation estimated Cardiac Effort in clinic on a 90ft walking space.




**Figure 6.** Agreement between in clinic vs at home assessment walk distances and cardiac efforts. (Top left) Bland-Altman plot of lap-estimated 6MWD at home vs lap-estimated 6MWD in clinic on a 30ft walking space. (Top right) Bland-Altman plot of lap-estimated Cardiac Effort at home vs lap-estimated Cardiac Effort in clinic on a 30ft walking space. (Bottom left) Bland-Altman plot of mean amplitude deviation estimated 6MWD at home vs mean amplitude deviation estimated 6MWD in clinic on a 30ft walking space. (Bottom right) Bland-Altman plot of mean amplitude deviation estimated Cardiac Effort at home vs mean amplitude deviation estimated Cardiac Effort in clinic on a 30ft walking space.